

## Vitamin D Testing

**Policy MP-056**

**Origination Date:** 06/24/2020

**Reviewed/Revised Date:** 05/21/2025

**Next Review Date:** 05/21/2026

**Current Effective Date:** 05/21/2025

### Disclaimer:

1. Policies are subject to change in accordance with State and Federal notice requirements.
2. Policies outline coverage determinations for U of U Health Plans Commercial, CHIP and Healthy U (Medicaid) plans. Refer to the "Policy" section for more information.
3. Services requiring prior-authorization may not be covered, if prior-authorization is not obtained.
4. **This Medical Policy does not guarantee coverage or payment of the service. The service must be a benefit in the member's plan and the member must be eligible for coverage at the time of service. Additional payment guidelines may be applied that are not included in this policy.**

### Description:

Vitamin D is a fat-soluble vitamin. Very few foods naturally contain vitamin D (fatty fish and eggs are the exception), so vitamin D is obtained primarily through fortified foods or supplements and dermal synthesis from exposure to sunlight. Vitamin D has two forms, ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), and several metabolites. Estimates of vitamin D requirements vary and depend in part upon sun exposure and the standards used to define a deficient state. It is more accurate to consider fat-soluble vitamin D as a steroid hormone, synthesized by the skin and metabolized by the kidney to an active hormone, calcitriol. Clinical disorders related to vitamin D may arise because of altered availability of the parent vitamin D, altered conversion of vitamin D to its predominant metabolites, altered organ responsiveness to hydroxylated metabolites and disturbances in the interactions of the vitamin D metabolites with PTH and calcitonin.

### Policy Statement and Criteria

#### 1. Commercial Plans/CHIP

**U of U Health Plans limits coverage for vitamin D (25-OH vitamin D) testing to specific circumstances demonstrated to impact health outcomes of its members.**

**Circumstances in which vitamin D (25-hydroxy vitamin D testing, (CPT® 82306) is covered:**

- A. Non-pregnant individual age 18 – 64 years with any of the following:

- i. Celiac Disease
- ii. Chronic kidney disease stage III or greater
- iii. Cirrhosis/Hepatic failure
- iv. Eating Disorder
- v. Hypocalcemia (persistent)
- vi. Hypercalcemia (persistent)
- vii. Hypercalciuria (persistent)
- viii. Hypervitaminosis D
- ix. Malabsorption syndromes including:
  - a. Cystic fibrosis;
  - b. Inflammatory Bowel Disease - Crohn's disease;
  - c. Bariatric surgery;
  - d. Radiation Enteritis.
- x. Obstructive jaundice
- xi. Osteomalacia
- xii. Osteosclerosis/petrosis
- xiii. Osteoporosis if:
  - a. T score of -2.5 and lower on DEXA scan; or
  - b. History of fragility fractures; or
  - c. FRAX > 3% 10-year probability of hip fracture or 20% 10-year probability of other major osteoporotic fracture; or
  - d. FRAX > 3% (any fracture) with T-score v. Initiating bisphosphonate therapy (Vit D level should be determined and managed as necessary before bisphosphonate is initiated).
- xiv. Osteopenia if:
  - a. FRAX > 3% 10-year probability of hip fracture or 20% 10-year probability of other major osteoporotic fracture; or
  - b. T score between -1.0 and -2.49 on DEXA scan
- xv. Rickets, acquired or congenital childhood
- xvi. Vitamin D deficiency on replacement therapy related to a condition listed above; to monitor the efficacy of treatment
- xvii. Nephrolithiasis
- xviii. Hyper/hypoparathyroidism
- xix. Chronic use of certain medications:

- a. Antiseizure medications;
  - b. Glucocorticoids;
  - c. AIDS/HIV medications;
  - d. Antifungals, e.g. ketoconazole;
  - e. Cholestyramine.
- xx. Granuloma-forming disorders:
- a. Sarcoidosis;
  - b. Tuberculosis;
  - c. Histoplasmosis;
  - d. Coccidiomycosis;
  - e. Berylliosis.

**Conditions for which 1, 25-OH vitamin D level (CPT® 82652) is covered:**

- A. Unexplained hypercalcemia (suspected granulomatous disease or lymphoma);
- B. Unexplained hypercalciuria (suspected granulomatous disease or lymphoma);
- C. Suspected genetic childhood rickets;
- D. Suspected tumor-induced osteomalacia;
- E. Nephrolithiasis or hypercalciuria.

**U of U Health Plans does NOT cover vitamin D testing for any other indication including screening in the general population as it is considered not medically necessary.**

**U of U Health Plans does NOT cover vitamin D testing (82306 or 82652 in any combination) more frequently than twice in a rolling 12-month period as it is considered not medically necessary for any diagnosis other than chronic kidney disease (CKD) or intestinal malabsorption.**

**U of U Health Plans does NOT cover vitamin D testing utilizing both CPT® 82306 and CPT® 82652 in combination as it is considered not medically necessary.**

## **2. Medicaid Plans**

**Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the U of U Health Plans Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website at: <https://medicaid.utah.gov/utah-medicaid-official-publications/> or the [Utah Medicaid code Look-Up tool](#)**

## **CPT/HCPCS codes covered by Utah State Medicaid may still require further evaluation to determine medical necessity for coverage.**

### **Clinical Rationale**

There is a paucity of evidence evaluating the benefit and harm of testing for vitamin D. Peer-reviewed scientific literature primarily investigates the effects of vitamin D supplementation, not testing. The Washington State Health Care Authority Health Technology Assessment Program published a technology assessment on vitamin D Screening and Testing in 2012. It was determined that no definitive conclusions can be drawn about the effectiveness of vitamin D screening or testing since no trials have been conducted to directly assess the impact of screening or testing on health outcomes, patient behavior, or clinical decision making. However, for some populations and outcomes, an association between serum levels and health outcomes and/or a positive effect of supplementation on health outcomes has been demonstrated. Thus, vitamin D screening has potential utility for identifying individuals who could benefit from the preventive or disease modifying effects of supplementation in these clinical situations when certain conditions are present or suspected to be present.

Subsequently, LeBlanc et al. in 2015 (updated in 2021) conducted a systematic review for the U.S. Preventive Services Task Force (USPSTF) to assess the benefits and harms of vitamin D screening in asymptomatic adults. The authors found “No study evaluated clinical outcomes or harms in persons screened versus not screened for vitamin D deficiency”. Limited evidence in persons not known to have conditions associated with vitamin D deficiency demonstrated that treating this deficiency with vitamin D may be associated with decreased risk for death in institutionalized elderly adults and a reduction in the average number of falls but not fractures. The authors concluded that future research is needed to reduce assay variability; determine appropriate thresholds for vitamin D deficiency; and clarify effects of screening, subsequent treatment, and the subpopulations most likely to benefit. The USPSTF still noted an “I” designation for this testing as routine screening outside of specific conditions being present in 2021.

Many professional societies/organizations have also provided guidance related to the proper role of vitamin D testing. These include the Endocrine Society Clinical Practice Guideline on Evaluation, Treatment, and Prevention of vitamin D Deficiency (Holick, et al., 2011) which recommends specific testing for vitamin D deficiency in individuals at risk for deficiency and do not recommend population screening for vitamin D deficiency in individuals who are not at risk. These guidelines also recommend using the serum circulating 25-hydroxyvitamin D [25(OH)D] level, measured by a reliable assay, to evaluate vitamin D status in patients who are at risk for vitamin D deficiency. As for serum 1,25-dihydroxyvitamin D [1,25(OH)2D] assay these guidelines do not recommend using this testing for screening (patients at risk) and are in favor of using it only in monitoring certain conditions, such as acquired and inherited disorders of vitamin D and phosphate metabolism. The authors note there is no evidence demonstrating benefits of screening for vitamin D deficiency at a population level. Such evidence would require demonstration of the feasibility and cost-effectiveness of such a screening strategy, as well as benefits in terms of important health outcomes. In the absence of this evidence, it is premature to recommend screening at large at this time. Currently, 25(OH)D measurement is reasonable to use in groups of people at high risk for vitamin D deficiency and in whom a prompt response to optimization of vitamin D status could be expected.

The American Academy of Pediatrics (AAP) Committee on Nutrition (Golden, et al., 2014) states that evidence is insufficient to recommend universal screening for vitamin D deficiency. The AAP report advises screening for vitamin D deficiency “only in children and adolescents with conditions associated

with reduced bone mass and/or recurrent low-impact fractures. More evidence is needed before recommendations can be made regarding screening of healthy black and Hispanic children or children with obesity. The recommended screening is measuring serum 25-OH-D concentration, and it is important to be sure this test is chosen instead of measurement of the 1,25-OH<sub>2</sub>-D concentration, which has little, if any, predictive value related to bone health.”

Whereas the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) have published a Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis (Camacho, et al., 2016) which includes the following recommendation for fundamental measures concerning bone health: Measure serum 25-hydroxyvitamin D (25[OH]D) in patients who are at risk for vitamin D insufficiency, particularly those with osteoporosis (Grade B).

Several societies including the AACE/ACE, The Obesity Society, American Society for Metabolic & Bariatric Surgery (ASMBS), Obesity Medicine Association, and American Society of Anesthesiologists in 2020 provided evidence-based recommendations for Perioperative nutrition, metabolic, and nonsurgical support of patients undergoing Bariatric procedures. They recommend baseline and annual postoperative evaluation for vitamin D deficiency is recommended after Roux-en-Y gastric bypass, sleeve gastrectomy, or laparoscopic biliopancreatic diversion without or with duodenal switch (Recommendation 53) (Mechanick, 2019). The American Society for Metabolic and Bariatric Surgery (ASMBS) Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients (Parrott, et al., 2017) specifically recommends routine pre- and post-weight loss surgery (WLS) vitamin D screening. The ASMBS states routine post-WLS screening refers to performing a nutrient assessment every 3–6 months in the first year and annually thereafter, unless otherwise specified.

As for circumstances involving primary hyperparathyroidism, Wilhelm, et al. in 2016 writing for the American Association of Endocrine Surgeons (AAES): made the recommendation to perform biochemical evaluation of suspected primary hyperparathyroidism including serum total calcium, PTH, creatinine, and 25- hydroxyvitamin D levels (strong recommendation; moderate quality evidence).

In cases of Crohn’s disease the American College of Gastroenterology (ACG) recommends including “Routine laboratory investigation: Initial laboratory investigation should include evaluation for inflammation, anemia, dehydration, and malnutrition” (Lichtenstein, et al., 2018). This includes testing for 25(OH) vitamin D. The ACG also make recommendations in assessment of Primary Sclerosing Cholangitis (Lindor, et al., 2015) to screen and monitor patients with advanced liver disease should be for fat-soluble vitamin deficiencies as fat-soluble vitamin deficiencies can occur in late stages of primary sclerosing cholangitis when patient becomes jaundiced. Levels of vitamins A, E, and D should be assessed in patients with advanced disease (Conditional recommendation, moderate quality of evidence).

The ACG Clinical Guideline on the Diagnosis and Management of Celiac Disease (Rubio-Tapia, et al., 2013) recommends people with newly diagnosed celiac disease should undergo testing and treatment for micronutrient deficiencies. Deficiencies to be considered for testing should include, but not be limited to, iron, folic acid, vitamin D, and vitamin B12. (Conditional recommendation, low level of evidence).

Evidence-based guidelines from the National Osteoporosis Foundation (NOF): The NOF’s Clinician’s Guide to Prevention and Treatment of Osteoporosis (Cosman, et al., 2014) notes serum 25-hydroxyvitamin D (25[OH]D) testing should be performed to evaluate for secondary causes of osteoporosis. It also states, “since vitamin D intakes required to correct vitamin D deficiency are so

variable among individuals, serum 25(OH)D levels should be measured in patients at risk of deficiency. Vitamin D supplements should be recommended in amounts sufficient to bring the serum 25(OH)D level to approximately 30 ng/ml (75 nmol/L) and a maintenance dose recommended to maintain this level, particularly for individuals with osteoporosis. It defines vitamin D insufficiency as a serum 25-hydroxyvitamin D (25[OH]D)<30 ng/ml (75 nmol/L).

## Applicable Coding

### CPT Codes

#### Possibly Covered Codes

<b>82306</b>	Vitamin D; 25 hydroxy, includes fraction(s), if performed
<b>82652</b>	Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed

#### Not Covered Codes

<b>0038U</b>	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative
--------------	---

### HCPCS Codes

No Applicable HCPCS Codes

### ICD-10 Codes

<b>A15.0-A19.9</b>	Tuberculosis	<b>E20.0</b>	Idiopathic hypoparathyroidism
<b>B20</b>	Human immunodeficiency virus [HIV] disease	<b>E20.8</b>	Other hypoparathyroidism
<b>B39.0-B39.9</b>	Histoplasmosis	<b>E20.9</b>	Hypoparathyroidism, unspecified
<b>C22.0-C22.9</b>	Malignant neoplasm of liver and intrahepatic bile ducts	<b>E21.0-E21.5</b>	Hyperparathyroidism and other disorders of parathyroid gland
<b>C23</b>	Malignant neoplasm of gallbladder	<b>E24.0-E24.9</b>	Cushing's syndrome
<b>C24.0-C24.9</b>	Malignant neoplasm of other and unspecified parts of biliary tract	<b>E41</b>	Nutritional marasmus
<b>C25.0-C25.9</b>	Malignant neoplasm of pancreas	<b>E55.0-E55.9</b>	Vitamin D deficiency
<b>C26.0-C26.9</b>	Malignant neoplasm of other and ill-defined digestive organs	<b>E63.9</b>	Nutritional deficiency, unspecified
<b>C83.80-C83.89</b>	Other non-follicular lymphoma	<b>E64.3</b>	Sequelae of rickets
<b>C84.00-C84.09</b>	Mycosis fungoides	<b>E67.2</b>	Megavitamin-B6 syndrome
<b>C84.10-C84.19</b>	Sezary disease	<b>E67.3</b>	Hypervitaminosis D
<b>C88.4</b>	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]	<b>E67.8</b>	Other specified hyperalimentation
<b>D13.0-D13.9</b>	Benign neoplasm of other and ill-defined parts of digestive system	<b>E68</b>	Sequelae of hyperalimentation
<b>D86.0-D86.89</b>	Sarcoidosis	<b>E83.30-E83.39</b>	Disorders of phosphorus metabolism and phosphatases
		<b>E83.50-E83.59</b>	Disorders of calcium metabolism
		<b>E84.0-E84.9</b>	Cystic fibrosis
		<b>E89.2</b>	Postprocedural hypoparathyroidism

<b>F50</b>	Eating disorders	<b>K91.82</b>	Postprocedural hepatic failure
<b>G40.001-G40.919</b>	Epilepsy	<b>L90.0</b>	Lichen sclerosus et atrophicus
<b>K50.00-K50.919</b>	Crohn's disease [regional enteritis]	<b>L92.0-L92.9</b>	Other diseases of digestive system
<b>K70.2</b>	Alcoholic fibrosis and sclerosis of liver	<b>L94.0</b>	Localized scleroderma [morphea]
<b>K70.30-K70.31</b>	Alcoholic cirrhosis of liver	<b>L94.1</b>	Linear scleroderma
<b>K71.10-K71.11</b>	Toxic liver disease with hepatic necrosis	<b>L94.3</b>	Sclerodactyly
<b>K71.7</b>	Toxic liver disease with fibrosis and cirrhosis of liver	<b>M05.00-M05.9</b>	Rheumatoid arthritis with rheumatoid factor
<b>K72.00-K72.91</b>	Hepatic failure	<b>M06.00-M06.9</b>	Other rheumatoid arthritis
<b>K74.0-K74.69</b>	Fibrosis and cirrhosis of liver	<b>M32.0-M32.9</b>	Systemic lupus erythematosus (SLE)
<b>K75.81</b>	Nonalcoholic steatohepatitis (NASH)	<b>M33.01-M33.09</b>	Juvenile dermatomyositis
<b>K76.0</b>	Fatty (change of) liver, not elsewhere classified	<b>M33.11-M33.19</b>	Other dermatomyositis
<b>K76.89</b>	Other specified diseases of liver	<b>M33.91-M33.99</b>	Dermatopolymyositis
<b>K82.0</b>	Obstruction of gallbladder	<b>M36.0</b>	Dermato(poly)myositis in neoplastic disease
<b>K82.8</b>	Other specified diseases of gallbladder	<b>M81.0-M81.8</b>	Osteoporosis without current pathological fracture
<b>K82.9</b>	Disease of gallbladder, unspecified	<b>M83.0-M83.9</b>	Adult osteomalacia
<b>K83.01-K83.9</b>	Other diseases of biliary tract	<b>M85.80-M85.9</b>	Other specified disorders of bone density and structure, various sites
<b>K85.10-K85.12</b>	Biliary acute pancreatitis	<b>M88.0-M88.9</b>	Osteitis deformans of various sites
<b>K86.2</b>	Cyst of pancreas	<b>N40.0-N40.9</b>	Benign prostatic hyperplasia
<b>K86.3</b>	Pseudocyst of pancreas	<b>N18.3</b>	Chronic kidney disease (CKD), stage III
<b>K86.81-K86.89</b>	Other specified diseases of pancreas	<b>N18.4</b>	Chronic kidney disease (CKD), stage IV
<b>K86.9</b>	Disease of pancreas, unspecified	<b>N18.5</b>	Chronic kidney disease (CKD), Stage V
<b>K87</b>	Disorders of gallbladder, biliary tract and pancreas in diseases classified elsewhere	<b>N25.81</b>	Secondary hyperparathyroidism of renal origin
<b>K90.0</b>	Celiac Disease	<b>Q78.0</b>	Osteogenesis imperfecta
<b>K90.0-K90.49</b>	Intestinal malabsorption	<b>Q78.2</b>	Osteopetrosis
<b>K90.81</b>	Whipple's disease	<b>Z21</b>	Asymptomatic human immunodeficiency virus [HIV] infection status
<b>K90.89</b>	Other intestinal malabsorption	<b>Z79.51-Z79.52</b>	Long term (current) use of steroids
<b>K90.9</b>	Intestinal malabsorption, unspecified	<b>Z79.899</b>	Other long term (current) drug therapy
<b>K91.2</b>	Postsurgical malabsorption, not elsewhere classified		

**References:**

1. ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. *Obstet Gynecol.* 2011 Jul;118(1):197-8. Reaffirmed 2019. Accessed June 2020. Available at URL address: <https://www.acog.org>
2. American Academy of Neurology. Policy and Guidelines. Accessed Jan 2020. Available at URL address: <https://www.aan.com/policy-and-guidelines/> and <https://www.aan.com/Guidelines/Home/ByStatusOrType?status=all>
3. American Association of Clinical Endocrinologists. AACE/ACE CLINICAL PRACTICE GUIDELINES. Accessed June 2020. Available at URL address: <https://www.aace.com>
4. American Association of Endocrine Surgeons. Practice Guidelines. Accessed June 2020. Available at URL address: <https://www.endocrinesurgery.org>
5. American College of Gastroenterology. Clinical Guidelines. Accessed June 2020. Available at URL address: <http://gi.org/clinical-guidelines/clinical-guidelines-sortable-list/>
6. American College of Rheumatology. Clinical Practice Guidelines. Accessed June 2020. Available at URL address: <https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines>
7. American Gastroenterological Association. Accessed June 2020. Available at URL address: <https://www.gastro.org/guidelines>
8. American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences. *J Am Geriatr Soc.* 2014 Jan;62(1):147-52. Accessed Jan 2020. Status: INACTIVE. Available at URL address: <https://geriatricscareonline.org/ProductAbstract/american-geriatrics-society-consensus-statement-vitamin-d-for-prevention-of-falls-and-their-consequences-in-older-adults/CL009/?param2=search>
9. American Thyroid Association. Guidelines and Surgical Statements. Accessed June 2020. Available at URL address: <https://www.thyroid.org/professionals/ata-professional-guidelines/>
10. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016--executive summary. *Endocr Pract.* 2016 Sep;22(9):1111-8.
11. Centers for Medicare & Medicaid Services (CMS). Local Coverage Determinations (LCDs) Alphabetical Index. Vitamin D Assay Testing. Accessed June 2020. Available at URL address: <https://med.noridianmedicare.com>
12. Charoenngam, N. (2021). "Vitamin D and Rheumatic Diseases: A Review of Clinical Evidence." *Int J Mol Sci* 22(19).
13. Chen FP, Lin YC, Lin YJ, et al. *Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.* 2024;30(7):616-623. doi:10.1016/j.eprac.2024.04.013.
14. Choosing Wisely® Initiative. Accessed Jan 2020. Available at URL address: <http://www.choosingwisely.org/clinician-lists/>
15. Cosentino, N., et al. (2021). "Vitamin D and Cardiovascular Disease: Current Evidence and Future Perspectives." *Nutrients* 13(10).
16. Cosman, F., et al. (2014). "Clinician's Guide to Prevention and Treatment of Osteoporosis." *Osteoporos Int* 25(10): 2359-2381. Accessed June 2020.
17. Golden, N. H., et al. (2014). "Optimizing bone health in children and adolescents." *Pediatrics* 134(4): e1229-1243.
18. Holick, M. F., et al. (2011). "Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline." *J Clin Endocrinol Metab* 96(7): 1911-1930.
19. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *J Am Coll Cardiol.* 2014 Jul 1;63(25 Pt B):2985-3023. Erratum in *J Am Coll Cardiol.* 2014 Jul 1;63(25 Pt B):3029-3030.
20. Kahwati LC, LeBlanc E, Weber RP, Giger K, Clark R, Suvada K, Guisinger A, Viswanathan M. Screening for Vitamin D Deficiency in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2021 Apr 13;325(14):1443-1463. doi: 10.1001/jama.2020.26498. PMID: 33847712.
21. LeBlanc, E. S., et al. (2015). "Screening for vitamin D deficiency: a systematic review for the U.S. Preventive Services Task Force." *Ann Intern Med* 162(2): 109-122.
22. Lichtenstein, G. R., et al. (2018). "ACG Clinical Guideline: Management of Crohn's Disease in Adults." *Am J Gastroenterol* 113(4): 481-517.
23. Lindor, K. D., et al. (2015). "ACG Clinical Guideline: Primary Sclerosing Cholangitis." *Am J Gastroenterol* 110(5): 646-659; quiz 660.

24. Mechanick, J. I., et al. (2019). "Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists - Executive Summary." *Endocr Pract* 25(12): 1346-1359.
25. Modan-Moses D, Levy-Shraga Y, Pinhas-Hamiel O, Kochavi B, Enoch-Levy A, Vered I, Stein D. High prevalence of vitamin D deficiency and insufficiency in adolescent inpatients diagnosed with eating disorders. *Int J Eat Disord*. 2015 Sep;48(6):607-14. doi: 10.1002/eat.22347. Epub 2014 Aug 18. PMID: 25130505.
26. Parrott, J., et al. (2017). "American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients." *Surg Obes Relat Dis* 13(5): 727-741.
27. Rubio-Tapia, A., et al. (2013). "ACG clinical guidelines: diagnosis and management of celiac disease." *Am J Gastroenterol* 108(5): 656-676; quiz 677.
28. Singer AG, McChesney C. Reduce unnecessary routine vitamin D testing. *Can Fam Physician*. 2023 Sep;69(9):620-622. doi: 10.46747/cfp.6909620. PMID: 37704241; PMCID: PMC10498906.
29. Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The assessment of fracture risk. *J Bone Joint Surg Am*. 2010 Mar;92(3):743-53. doi: 10.2106/JBJS.I.00919. PMID: 20194335; PMCID: PMC2827823.
30. UpToDate® (2023). "Management of celiac disease in adults". Literature current through April 2023. Topic last updated: February 1, 2023. Version 43.0. Topic 4777. Accessed: May 31, 2023. Available at: <https://www.uptodate.com>
31. UpToDate® (2023). "Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment". Literature current through March 2024. Topic last updated: September 30, 2023. Version 69.0. Topic 2022. Accessed: April 16, 2024. Available at: <https://www.uptodate.com>
32. UpToDate® (2022). "Vitamin D insufficiency and deficiency in children and adolescents". Literature current through April 2023. Topic last updated: April 12, 2022. Version 59.0. Topic 14590. Accessed: May 31, 2023. Available at: <https://www.uptodate.com>
33. UpToDate® (2025). "Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications". Literature review current through: April 2025. Last Topic Update: March 4, 2025. Accessed: May 19, 2025. Available at: <https://www.uptodate.com>
34. U.S. Preventive Services Task Force (USPSTF). Final Recommendation Statement Vitamin D Deficiency: Screening. November 2021. Accessed June 12, 2022. Available at URL address: <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-d-deficiency-screening>
35. U.S. Preventive Services Task Force (USPSTF). Final Recommendation Statement Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication. April 2018. Accessed June 2020. Available at URL address: <https://www.uspreventiveservicestaskforce.org>
36. Washington State Health Care Authority. Health Technology Assessment Program (HTA). Vitamin D Screening and Testing. Final Evidence Report November 16, 2012. Accessed June 2020. Available at URL address: [https://www.hca.wa.gov/assets/program/vitd\\_finalrpt\\_111612\[1\].pdf](https://www.hca.wa.gov/assets/program/vitd_finalrpt_111612[1].pdf)
37. Wilhelm, S. M., et al. (2016). "The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism." *JAMA Surg* 151(10): 959-968.

**Disclaimer:**

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

U of U Health Plans makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. U of U Health Plans updates its Coverage Policies regularly, and reserves the right to amend these policies and give notice in accordance with State and Federal requirements.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from U of U Health Plans.

"University of Utah Health Plans" and its accompanying logo, and its accompanying marks are protected and registered trademarks of the provider of this Service and or University of Utah Health. Also, the content of this Service is proprietary and is

protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association